美国甲状腺癌临床试验:理解趋势以最大化影响
该回顾性研究利用ClinicalTrials.gov分析1998至2015年甲状腺癌临床试验的模式、发表与资助情况,共识别73项试验,其中96%为药物研究,仅14%涉及放疗、4%涉及手术,29%的试验发表了结果,26%报告了NIH资助,总资助金额为1 845 567 484美元,平均资助金额为97 135 131美元。
要点
- 甲状腺癌试验中药物研究占96%,放疗仅14%、手术仅4%。
- 仅29%的试验发表了结果,26%的试验报告了NIH资助。
- 作者建议更好地平衡治疗方式并开展同行评议的阳性与阴性结果报告。
核心结论
- 本研究首次证明药物试验在甲状腺癌中占主导地位,并量化了NIH资助金额。
- 放疗和手术尽管是标准治疗,但研究不足。
- 作者建议更好地平衡治疗方式并开展同行评议的阳性与阴性结果报告。
研究设计与样本
- 回顾性研究,利用ClinicalTrials.gov分析1998至2015年甲状腺癌试验,并从PubMed.gov和NIH RePORTER获取发表与资助信息。
- 共识别73项甲状腺癌试验,来自217 000项试验。
主要发现
- 96%的试验研究药物,仅14%涉及放疗,4%涉及手术。
- 仅29%的试验发表了结果,26%的试验报告了NIH资助。
- 总资助金额为1 845 567 484美元,平均资助金额为97 135 131美元。
临床怎么用
- 作者建议更好地平衡治疗方式并开展同行评议的阳性与阴性结果报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to understand thyroid cancer study modalities, publications, and grants. This provides scope, resources, and dissemination patterns to inform future directions for research and policy. METHODS: A retrospective study of thyroid cancer trials using ClinicalTrials.gov was performed. Publication and grant awards were sourced using PubMed.gov and NIH RePORTER, respectively. RESULTS: Seventy-three thyroid cancer trials were identified out of 217 000 from 1998 to 2015. Drugs were studied in 96% of all trials. Only 14% of all trials included radiation, and 4% included surgery. Only 29% of trials published their results, NIH funding was reported for 26% of trials. Total funding was $1 845 567 484 (average award: $97135131). CONCLUSION: This study is the first to prove that drug trials predominate in thyroid cancer and quantify NIH dollars awarded. Radiation and surgery are underrepresented, despite being standard of care. We recommend better balance of therapeutics and peer-reviewed reporting of positive and negative results. LEVEL OF EVIDENCE: Level 1a evidence.
引用
- Hsieh A, Murchison C, Devaiah A, et al. Thyroid cancer clinical trials in the United States: Understanding trends to maximize impact. Head Neck. 2019. PMID: 30779240. doi:10.1002/hed.25703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。